Market Currents
Vertex Pharmaceuticals (VRTX) and fellow collaborator Alios BioPharma announce positive results...
-
Monday, July 30, 2012, 4:17 PM ETVertex Pharmaceuticals (VRTX) and fellow collaborator Alios BioPharma announce positive results from a viral kinetic study of its nucleotide hepatitis C treatment ALS-2200, saying the drug was well-tolerated, and no patients discontinued due to adverse events. Based on the data, Vertex plans to begin Phase 2 studies this year of 12-week all-oral regimens. Shares +7.5% AH.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
